Active, not recruitingPhase 2
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Key facts
- Who runs it
- H. Lundbeck A/S
- Where
- Ann Arbor and St Louis, United StatesSee the 2 sitesAlso in 8 other countries, 26 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 16 people enrolled
- Started
- 19 Jun 2024
- Expected to end
- 31 Oct 2027
- Type of study
- Interventional
- Treatments tested
- Lu AG13909
- Record updated
- 16 October 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- The participant is a man or woman with a confirmed diagnosis of adrenocorticotropic hormone (ACTH) driven CD of pituitary source as per current guidelines
- Morning plasma ACTH levels > lower limit of normal (LLN) and
- Evidence of a pituitary origin of the excess ACTH:; Either MRI confirmation of pituitary adenoma >6 millimeters (mm), or ii. inferior petrosal sinus gradient >2, or iii. histopathology confirmation of ACTH-secreting tumour
- The participant has a 24-hour UFC >1.5 × ULN (the mean of ≥3 days of 24-hour urine collection)
- Apart from CD and associated well-controlled comorbidities (for example, diabetes mellitus and hypertension), the participant is generally healthy in the opinion of the investigator and based on medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the safety laboratory tests
- For participants on medical treatment for hypercortisolism due to CD, pre-defined washout periods must be completed prior to the Baseline efficacy assessments
Who cannot take part
- The participant has immediate need for pituitary surgery within 6 months from screening in the opinion of the investigator
- The participant had pituitary surgery <3 month prior to screening
- The participant had pituitary radiotherapy within the last 10 years; Other protocol-defined criteria apply
- The participant has a history of known hypersensitivity or intolerance to Lu AG13909 or its excipients
- The participant has severe CD per investigator judgement; among others, this could be participants with:; poorly controlled hypertension ii. poorly controlled diabetes mellitus iii. severe psychiatric illness iv. compression of the optic chiasm causing any visual field defect or risk thereof v. very high risk of thromboembolic events
- The participant has a clinically significant abnormal laboratory value, ECG parameter, vital signs value, or other safety findings at the Screening Visit that indicate a potential risk to the participant's safety if enrolled, in the opinion of the investigator
- The participant is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not willing to use adequate contraceptive methods
Where in United States
Also in 8 other countries, 26 sites
- University of Michigan Health-A. Alfred Taubman Health Care CenterAnn Arbor, United StatesNo longer taking part
- Washington University School of Medicine in St. LouisSt Louis, United StatesNo longer taking part
About the trial
What the trial wants to find out
This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about
Read full original descriptionShow less
1. the effect of Lu AG13909 on cortisol levels. 2. the safety and tolerability of Lu AG13909. 3. the pharmacokinetic parameters of Lu AG13909 (how the drug is absorbed, distributed, and processed by the body).
The group in the trial
- Lu AG13909Treatment being tested
Participants will first receive Lu AG13909 IV per predefined dosing schedule. Participants will then receive Lu AG13909 SC per predefined dosing schedule.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease
- Record updated
- 16 October 2026